Background {#Sec1}
==========

An informed consent form (ICF) is mandatory and essential in most studies involving human subjects as it is a primary vehicle for disclosure of information and documentation of consent \[[@CR1], [@CR2]\]. An observation of the current research practice reveals that ICFs continue to increase in length and complexity in an attempt to comply with regulatory requirements \[[@CR3]--[@CR6]\], which increasingly require more and more elements to address past and present unethical practice \[[@CR7], [@CR8]\]. Lengthy and complex ICFs decrease the ability of potential participants to comprehend the ICF content and exercise their autonomy in decision making to participate in a study \[[@CR9]\]. ICFs have been gradually turned into legal documents for the protection of researchers and sponsors rather than documents with relevant information for decision making of research participants \[[@CR10]\].

In an attempt to make ICFs comprehensible, the extent of information disclosure has been the subject of debates \[[@CR11]--[@CR13]\]. Lengthy ICFs with full disclosure of everything may obscure the important and relevant information for decision making whether to participate in a study \[[@CR14]\]. Exhaustive disclosure of detailed information of every single aspect related to the study may overwhelm potential research participants with too excessive information \[[@CR15]\]. Based on a systematic review on the desired information by potential participants of biomedical research, there is limited empirical evidence on this subject \[[@CR16]\]. Generally, the type and extent of information considered as adequate and relevant for a person to make a decision are subjective and difficult to define. In addition, some information perceived as relevant and important by some research participants, with respect to their cultural context, may be absent in even a lengthy ICF as it is not required by applicable laws and regulations \[[@CR13]\]. To address these issues, empirical data related to the content and extent of information that research participants require for their decision making are needed. The objective of this study was to determine the perspectives of research participants about the information they need for their decision making when they are invited to participate in biomedical research.

Methods {#Sec2}
=======

Study design and settings {#Sec3}
-------------------------

This multi-center, cross-sectional, descriptive survey was conducted by the Forum for Ethical Review Committees in the Asian and Western Pacific region (FERCAP) Multi-Country Research Team in 7 FERCAP-member countries, i.e., India, Indonesia, Malaysia, Philippines, Sri Lanka, Taiwan, and Thailand. The duration of this study was three months, from June 1 to August 31, 2017, with a two-week extension in some countries where a sample size was not met within the three-month period.

Study material {#Sec4}
--------------

An anonymous, paper-based, structured and self-administered questionnaire was developed and reviewed by a group of FERCAP professionals with expertise in research surveys, biomedical research, research ethics, and informed consent. Survey items were developed based on the essential elements required by three major ethical guidelines and regulations, i.e., Declaration of Helsinki \[[@CR1]\], the International Conference on Harmonization (ICH) for Good Clinical Practice (GCP) \[[@CR2]\], and US Code of Federal Regulations \[[@CR17]\]. A content validity test was conducted to establish that individual items were relevant to the construct being measured and that key items had not been omitted in the questionnaire \[[@CR18]\]. The questionnaire asked participants to indicate how important each item was by giving a rating from 1 to 5 using a modified Likert scale \[[@CR19]\]: 1 = not important, 2 = slightly important, 3 = moderately important, 4 = fairly important, and 5 = very important. There were open-ended questions in the questionnaire where the participants could suggest any additional elements or information that they would like to receive. Demographic data (age, sex, educational level, nationality, and occupation) and the participants' preference in page length were included in the questionnaire. The think-aloud technique was used to assess how respondents interpreted each item and response anchor \[[@CR20]\]. The questionnaire was then finalized and translated into the local language for use in each participating country. The questionnaires in local languages were back-translated into English by independent individuals who are fluent in both local and English languages and checked against the original questionnaire. The translated questionnaire was piloted in a small group of individuals who were members of the target population within each respective country.

Study population and sample size determination {#Sec5}
----------------------------------------------

This study enrolled individuals who were participating in ongoing biomedical research -- a research study relating to biology and medicine for healthcare purposes -- at various participating centers (clinical research units or comparable settings) in 7 countries. Individuals who refused to answer the questionnaire for any reason or had communication difficulties due to language problems or cognitive disabilities were excluded.

The sample size for this study was meant to yield a representative sample under the assumption that the quantity of interest is measured by a Likert scale. Following the formula described in Park & Jung (2009) \[[@CR21]\], a sample size of at least 231 would be adequate when a 5-point scale was used for each Likert-item (k = 5), with a coefficient of variation of a population (C) = 0.5, a relative tolerable error (D) = 5%, and a pairwise correlation coefficient (ρ) = 0.5. The present study was initially planned to enrol, at least, 300 participants in each country based on an approximate estimate of 20% of missing data due to some participants who might skip certain questions or items that they were not comfortable with.

Study procedure and data collection {#Sec6}
-----------------------------------

Data were collected through an anonymous, self-administered, structured, paper-based questionnaire. No written consent was required for this survey study as an individual participant's voluntary completion of the questionnaire was presumed as consent. Site investigators collaborated with research staff at clinical research units or comparable settings and informed research participants in biomedical research about this ICF study. Instructions were provided by research staff to potential participants that they could refuse to answer the questionnaire for any reason; they could skip any question that they were unwilling to answer; and they would not be treated differently because of the responses they gave in the questionnaire. When participants agreed to take part in this survey, research staff gave them the questionnaire. The participants could complete the questionnaire at any time and returned it to the collection box located at participating centers.

Ethical considerations {#Sec7}
----------------------

The study was conducted in compliance with the Declaration of Helsinki 2013. The study protocol and related documents obtained ethical approval from local ethics committees prior to the commencement of the survey in each center. This study was considered 'minimal-risk' research since it involved only the use of a questionnaire with no sensitive questions. The information was recorded in an anonymous manner. The participants could skip any question that they did not want to answer. Answering the questionnaire and returning it to the collection box implied the participants' voluntary consent for the investigators to use their answers to meet the research objective. No separate written consent was required to ensure the participants' anonymity.

Statistical analysis {#Sec8}
--------------------

Data from 7 countries were gathered, analyzed, and presented as frequency and percentage, mean and standard deviation (SD), or median and interquartile range (IQR), as appropriate. For the participants' preference in page length, 'no limit' or more than 30 pages was transformed to the value of 30 for analysis. Likert scale responses of each item were analyzed using parametric approaches \[[@CR22]--[@CR24]\]. Differences of variables among countries were done using the one-way analysis of variance (ANOVA), followed by Tukey post hoc test. The association between independent variables (i.e., sex, age, education, occupation, and type of research involved) and the mean score of each item was assessed using multivariable regression analysis. Statistical analyses were performed using SPSS (IBM Corp. Release 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). A *p* value of less than 0.05 was considered to indicate statistical significance.

Results {#Sec9}
=======

This FERCAP Multi-Country ICF study recruited research participants from 54 study sites in 7 countries. Of the 2484 questionnaires distributed, 2113 (85.1%) were returned (Table [1](#Tab1){ref-type="table"}). Demographic data of the respondents are shown in Table [2](#Tab2){ref-type="table"}. The majority of the respondents were female (57.9%), middle-aged adults (aged 43.3 ± 16.2 years, range 15--90 years), had a high-school level of education or lower (64.5%).Table 1Number of questionnaires distributed and collected by each countryCountrySite (*n*)Questionnaires distributed (*n*)Questionnaires collected (*n*)India4434410(94.5%)Indonesia1362299(82.6%)Malaysia28508508(100.0%)Philippines12508267(52.6%)Sri Lanka6335303(90.4%)Taiwan1229229(100.0%)Thailand210897(89.8%)**5424842113(85.1%)**Table 2Demographic data of the respondentsCharacteristics of the respondents*n* (%)Sex Male884(42.1%) Female1215(57.9%)Age 15--30 years638(30.4%) 31--45 years546(26.0%) 46--60 years514(24.5%) 61--90 years401(19.1%)Educational level High school or lower1331(64.5%) Bachelor/diploma degree525(25.4%) Master/doctor degree208(10.1%)Occupation Healthcare profession245(12.4%) Non-healthcare profession^†^1730(87.6%)Type of research involved Experimental research1234(59.8%) Observational research830(40.2%)^†^Non-healthcare profession, including students, housewives, retirees, and the unemployed

Overall, the respondents wanted to know most elements of the ICF content required (Table [3](#Tab3){ref-type="table"}), with mean scores ranging from 3.58 (about wanting to know the number of participants) to 4.47 (for major foreseeable risk) as shown in Fig. [1](#Fig1){ref-type="fig"}. All of the 37 items were rated as 'moderately important' or higher among approximately 80% of the respondents to as high as 97.4% of them highly interested in the direct benefit of research (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). None of the items were considered 'slightly important' or lower in more than one-third of the respondents from any country. Statistically significant differences were found among countries in the mean score of all the 37 items when one-way ANOVA was applied (*p* \< 0.001) (data not shown).Table 3The element and extent of information that research participants wanted to receiveElementAbbreviation*n*Extent of informationMeanSESDMedianIQR*1. General items* 1.1 Title of researchTitle(*n* = 2100)4.330.0210.9415(4--5) 1.2 Name of researchersName(*n* = 2091)4.080.0241.0884(4--5) 1.3 Affiliation or organization of researchersAffil(*n* = 2083)4.100.0231.0354(4--5) 1.4 Recognition that this is researchResea(*n* = 2095)4.290.0210.9635(4--5) 1.5 Contact information regarding the research studycInfo(*n* = 2040)4.290.0200.8995(4--5) 1.6 Contact information about the participant's rightcInfoR(*n* = 2035)4.260.0210.9325(4--5) 1.7 Source of funds and sponsorsSpons(*n* = 2082)3.750.0271.2334(3--5) 1.8 Conflict of interestCoi(*n* = 2020)3.790.0271.2284(3--5)*2. Study-specific items* 2.1 Background and rationale of researchBackg(*n* = 2084)4.160.0210.9664(4--5) 2.2 Purpose of researchPurp(*n* = 2093)4.350.0190.8685(4--5) 2.3 Eligibility of the participantEligib(*n* = 2104)4.280.0200.9155(4--5) 2.4 Study design of researchDesig(*n* = 2078)3.960.0231.0714(3--5) 2.5 Interventions under investigationInterv(*n* = 2080)4.370.0200.8955(4--5) 2.6 Common adverse effects of the interventioncoAE(*n* = 2082)4.450.0190.8575(4--5) 2.7 All possible adverse effects of the interventionallAE(*n* = 2086)4.360.0200.9335(4--5) 2.8 Other options or alternative treatmentsAltern(*n* = 2088)4.020.0241.0934(3--5) 2.9 Duration of the participant's participationDurat(*n* = 2069)4.170.0210.9714(4--5) 2.10 Schedule and procedureProc(*n* = 2089)4.290.0200.8945(4--5) 2.11 Identification of any experimental procedureseProc(*n* = 2075)4.110.0221.0134(4--5) 2.12 Number of participants involvedNumb(*n* = 2092)3.580.0271.2184(3--5) 2.13 Criteria for terminationTerm(*n* = 2045)4.230.0220.9754(4--5)*3. Items related to the subject's right* 3.1 Voluntary participationVolun(*n* = 2093)4.190.0221.0144(4--5) 3.2 Consequence of withdrawalcWith(*n* = 2039)4.040.0241.0974(4--5) 3.3 Right to receive new informationnInfo(*n* = 2048)4.250.0200.9274(4--5)*4. Items related to risk-benefit* 4.1 Major foreseeable riskmjRis(*n* = 2077)4.470.0200.9025(4--5) 4.2 Minor foreseeable riskmiRis(*n* = 2077)4.250.0210.9685(4--5) 4.3 Possibly unforeseeable riskufRis(*n* = 2043)4.270.0241.0645(4--5) 4.4 Direct health benefitdBene(*n* = 2088)4.470.0170.7935(4--5) 4.5 Indirect benefitiBene(*n* = 2096)4.310.0190.8655(4--5) 4.6 Societal benefitsBene(*n* = 2049)4.300.0200.9015(4--5) 4.7 Post-trial benefit or provisionpBene(*n* = 2048)4.230.0210.9504(4--5)*5. Items related to data and sample storage* 5.1 Confidentiality and the limit of confidentialityConfi(*n* = 2048)4.290.0220.9845(4--5) 5.2 Storage of human materialStora(*n* = 2041)3.970.0251.1484(3--5) 5.3 Reuse of human materialReuse(*n* = 2043)4.040.0251.1134(4--5)*6. Items related to monetary issues* 6.1 Payment and/or remunerationPaym(*n* = 2040)3.850.0261.1564(3--5) 6.2 Anticipated expenseExpen(*n* = 2025)4.000.0241.0994(4--5) 6.3 Compensation for injuryCompe(*n* = 2038)4.320.0200.9125(4--5)*IQR* interquartile range, *SD* standard deviation, *SE* standard error of the meanFig. 1The element and extent of information that research participants wanted to receive

Major foreseeable risk, direct benefit, and common adverse effects of the intervention were considered to be of most concern among the respondents (with mean scores of 4.47, 4.47, and 4.45, respectively) as shown in Fig. [1](#Fig1){ref-type="fig"}. In contrast, items about payment and/or remuneration, conflict of interest, the source of funds and sponsors, and the number of participants involved were considered to be of relatively less concern (with mean scores of 3.85, 3.79, 3.75, and 3.58, respectively). Nevertheless, there was slight variation in the items that were of most and of least concern among research participants in different countries (Table [4](#Tab4){ref-type="table"}).Table 4Ranks of the elements considered to be of most concern by research participants from each countryThe values that are more than 'mean + 1 SD' (considered to be of most concern) is in RED columns; those within 'mean ± 1 SD' is in YELLOW columns; and those less than 'mean -- 1 SD' (considered to be of least concern) is in GREEN columns

Demographic characteristics were found to be associated with the scores in several items. Higher scores in the desire to receive detailed information were associated with female gender (in 34 out of the 37 items), healthcare profession (in 24 out of the 37 items), younger age (in 11 out of the 37 items), and higher educational levels (in 10 out of the 37 items) (see Additional file [2](#MOESM2){ref-type="media"}: Table S2). Those participating in experimental research wanted more information in 30 out of the 37 items, as compared to those participating in observational research.

The maximum, acceptable number of pages in the ICF that research participants preferred to read was 6.3 ± 6.1 pages (median, 5 pages; IQR, 2--8 pages). However, this value varied among countries. The Taiwanese respondents reported the longest maximum, acceptable number of pages that they would read (12.3 ± 10.8 pages, *n* = 174), followed by the Filipino (7.7 ± 6.5 pages, *n* = 200), Malaysian (7.0 ± 5.7 pages, *n* = 438), Thai (5.3 ± 3.1 pages, *n* = 22), Indian (5.0 ± 3.2 pages, *n* = 378), Indonesian (4.1 ± 3.3 pages, *n* = 242), and Sri Lankan respondents (3.7 ± 3.3 pages, *n* = 213) (see Additional file [3](#MOESM3){ref-type="media"}: Table S3). Multivariable analysis identified factors that were associated with the maximum, acceptable number of pages in the ICF, i.e., occupation (healthcare profession vs. non-healthcare profession, *p* \< 0.001) and type of research involved (experimental vs. observational, *p* \< 0.001). When compared to their counterparts, research participants in the healthcare profession and those participating in the experimental research were more agreeable to reading longer ICFs (8.6 vs. 5.9 pages, *p* \< 0.001; 6.8 vs. 5.5 pages, *p* \< 0.001, respectively) (see Additional file [4](#MOESM4){ref-type="media"}: Figure S1).

There were 58 comments from 56 respondents, suggesting additional information needs. The majority of these comments showed their desire to know about whether to be informed of research results (n = 37) and the location where the research will be conducted (*n* = 8). A few respondents mentioned that they wanted to receive information about legal liability related to research (n = 4), other study sites involved (n = 2), clinical phase of the trial (n = 2), status of the trial, testimony, and approval (n = 2), research budget (n = 2), and related sources of information (n = 1).

Discussion {#Sec10}
==========

This FERCAP Multi-Country ICF study is the largest empirical study on this subject, involving 2113 actual research participants from 54 study sites in 7 countries. It attempted to determine the information that research participants considered to be of importance for their decision making whether to participate in biomedical research. The results indicate that the ICF elements required by ethical guidelines and regulations concur with the information the majority of research participants in 7 Asia-Pacific countries want to know.

The top three items which were of most concern to the respondents in this study were related to the concepts of risks and benefits (i.e., major foreseeable risk, direct benefit, and common adverse effects of the intervention). This finding is consistent with previous numerous studies indicating that research participants regard the risk and benefit associated with their participation to be more important than the general nature or technical details of research \[[@CR25]--[@CR27]\]. Thus, such information should be made a salient feature of an ICF when enrolling potential participants. While the written ICF provided in biomedical research should contain the necessary elements, it should be properly edited and streamlined to ensure concise information to reflect the results of this study. A participant-oriented approach that considers the importance of each element and emphasis on items perceived as more important than others could adequately address participant needs and avoid unnecessarily lengthy details that are of no interest to them \[[@CR13]\]. Information should be provided to the extent that it does not detract from what participants want to know and what is needed for a valid consent (i.e., sufficient information, comprehension, and voluntariness) \[[@CR28]\]. Information relating to the concepts of risks and benefits, for example, should be described extensively and made salient to potential research participants, while the general nature or technical details of research can be described briefly.

Disclosure requirements based on the elements required in the three major ethical guidelines and regulations -- the Declaration of Helsinki \[[@CR1]\], ICH GCP \[[@CR2]\], and US federal regulations \[[@CR17]\] -- are generally sufficient to cover all the aspects that most research participants would like to know. However, this study identified additional information that some participants want to be informed about. Information regarding the disclosure of individual results to participants at the end of the study is one of the elements that a sizable number of participants would like to know. This finding is in line with a recent systematic review reporting that several participants wanted to be told about dissemination of study results \[[@CR16]\]. This issue has lately been addressed in the revised US Federal Policy for the Protection of Human Subjects, promulgated in January 2017, that requires *"a statement regarding whether clinically relevant research results, including individual research results, will be disclosed to subjects, and if so, under what conditions"* \[[@CR7]\]. Nevertheless, it is important to note that disclosure of individual research results (IRRs) might pose psychosocial risks to research participants and their relatives in some settings, especially in genetic-association research \[[@CR29]\]. Hence, conditions for disclosure of IRRs should be predefined, e.g., the results that will be conveyed to the participants should be analytically valid, medically important, and actionable, with respect to the participants' preference \[[@CR30]--[@CR32]\]. In addition, a few respondents raised concerns about legal liability related to research while another wanted to know other study sites involved. When individuals would like to obtain certain additional information that may be relevant to their concerns, investigators may be required to disclose or provide them on a case-by-case basis \[[@CR28]\].

The analysis of the respondents' acceptable page length suggests that an approximately 6-page-long ICF seems to be acceptable to general populations in 7 countries across the Asia-Pacific region. This result is in line with other evidence promoting the use of short and concise ICFs in biomedical research \[[@CR33]\]. As shown in a previous empirical study on the preferred length of ICFs, most participants preferred concise, rather than detailed information when they made a decision on trial participation \[[@CR11]\]. Another evidence also suggested that a concise ICF is as valid as a detailed, standard ICF to comply with ethical requirements \[[@CR34]\]. Although concise forms may not be able to improve participants' satisfaction with the consent process in all settings, they still have other advantages to the readers as ones are less likely to thoroughly read long forms and wholly absorb extensive information \[[@CR35]\]. Recently, there has been a major change in the ethical guidelines and regulations that encourages investigators and sponsors to summarize relevant and important information in a few pages \[[@CR7], [@CR8]\]. An ICF used in biomedical research should no longer be an unduly long document, with key information often being hard to find \[[@CR33]\]. Concise ICFs with complete information as required by regulations can be developed, for example, using the SIDCER ICF methodology, which has recently been validated and published \[[@CR36]--[@CR39]\]. This methodology requires a thorough understanding of the protocol followed by the summarized information relevant to the interest and concerns of research participants \[[@CR36]\]. Visual aids such as summary tables, highlighting keywords and pictographs should be used, when appropriate, to simplify and help participants understand detailed and complex information \[[@CR36], [@CR40]\]. Nevertheless, some groups of participants, such as the Taiwanese, might indicate a preference for a relatively longer ICF which contains more detailed and comprehensive information. Supplementary provision of detailed information could be offered to such groups in additional papers (e.g., appendices) or via websites \[[@CR25], [@CR33]\].

A closer examination revealed that female participants, healthcare professionals, younger age groups, and those with high educational levels wanted to receive more information about several items when compared to their counterparts. This indicates the different needs of different groups for relevant biomedical or clinical trial information \[[@CR41]\]. Furthermore, research participants from different countries showed slight variation in their interests in each element. This is in line with other studies which suggested that information needs may somewhat vary across diverse socioeconomic backgrounds and cultural settings \[[@CR42]--[@CR44]\]. However, there is also a possibility that the difference of variables among countries might not be a genuine difference in ethical views; rather, it might be influenced by response styles across countries or cultural backgrounds \[[@CR45]\].

The results of this extensive multi-country survey, involving over 2000 actual research participants at 54 study sites across 7 Asia-Pacific countries, may be considered to be representative of the perspectives of general populations in the Asia-Pacific region. However, this study has a limitation as it lacks data on the perspectives of those asked to provide surrogate consent for others (e.g., parents or other legally acceptable representatives). It is reasonable to assume that the content and extent of information needed among surrogates may be different from what we observed among actual research participants in this study \[[@CR46], [@CR47]\]. In addition, different levels of research risk (e.g., low-risk studies with little or no intervention versus high-risk studies with invasive interventions) may result in different needs for trial information among research participants \[[@CR25], [@CR40]\]. Further research is required to help tailor ICFs toward more specific types of biomedical research, including biobank research, and population subgroups, such as the study previously done by Casarett et al. for pain research \[[@CR48]\].

Conclusions {#Sec11}
===========

In summary, what research participants would like to be informed of mostly concurred with the elements of the ICF content required by the current ethical guidelines and regulations. However, some elements may be more important than others and such information should be made salient to research participants. The study results provide important insights to better address the challenges of determining the extent of information in ICFs that is considered to be important and adequate from research participants' perspectives.
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